← brief for 2026-11-01 · Slowing decline

Semaglutide As a Multiorgan Therapeutic Agent: Evidence for Cardiovascular, Renal, and Hepatic Benefits

Article A Not peer reviewed Meta-analysis or large trial

Key takeaways

This review summarizes large trials of semaglutide, a diabetes drug. It shows the drug slows kidney decline and protects the heart. It also helps with liver health. The evidence comes from big studies with many people.

Who did this work

Subashini R · Arthanareeswaran S · Shifa Sidhiq Fatima C · Sandhiya V

Source

Article · OpenAlex, Kidney disease concept sweep (verified C2778653478) · 2026-10-31
https://doi.org/10.5281/zenodo.23838708